All News

2019

January

Media Release / Jan 16, 2019

Sandoz Inc. launches SYMJEPI™ (epinephrine) in the US

Read More
Media Release / Jan 16, 2019

Sandoz selects three finalists for Healthcare Access Challenge (Sandoz HACk) from over 400 global entries

Read More
Media Release / Jan 07, 2019

Sandoz and Pear Therapeutics Announce US Launch of reSET-O™ to Help Treat Opioid Use Disorder

Read More
2018

December

Media Release / Dec 10, 2018

Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O™ to Treat Opioid Use Disorder

Read More
Media Release / Dec 06, 2018

Update on Launch Plans for SYMJEPI™ (epinephrine) in the US

Read More
Media Release / Dec 06, 2018

Sandoz biosimilar Zarxio™ (filgrastim-sndz) reduced out-of-pocket costs for Medicare patients with breast cancer versus the reference medicine

Read More

November

Media Release / Nov 19, 2018

Sandoz and Pear Therapeutics announce launch of reSET® for treatment of patients with Substance Use Disorder

Read More
Media Release / Nov 08, 2018

Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)

Read More
Media Release / Nov 02, 2018

Sandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needs

Read More

October

Media Release / Oct 31, 2018

Sandoz receives US FDA approval for biosimilar Hyrimoz™ (adalimumab-adaz)

Read More